Skip to main content
Clinical Trials/IRCT20200518047497N2
IRCT20200518047497N2Not yet recruitingPhase 3

Effect of Dinvl medicinal herb on improving of clinical and paraclinical symptoms in patients with COVID-19 :A Randomized Controlled Trial

Zahravi Pharmaceutical Company0 sites80 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
15 years to no limit (—)
Sex
All

Inclusion Criteria

  • COVID-19 patients aged 15 years and older who newly admitted (first day of hospitalization)
  • Having definite COVID-19 disease
  • Obtaining informed consent to participate in the trial
  • Non-participation in another clinical trial simultaneously

Exclusion Criteria

  • Having liver or renal failure according to the patient's statement, physician examination or based on creatinine, SGOT, SGPT, LDH tests.
  • Immunodeficiency (treated with Corticosteroids over 12.5 mg / d Prednisolone for more than two weeks, chemotherapy, malignancies, organ transplants, HIV patients, other viral diseases.
  • Having other infectious diseases according to the diagnosis of the physician and the information of medical record.
  • Pregnancy (according to the patient's statement and examination by a physician).
  • Breastfeeding (according to the patient's statement).

Investigators

Similar Trials

Effect of Dinvl on improving of clinical... | Clinical Trial